Federal judge rules in favor of Sanofi, Regeneron in patent suit over cholesterol drugs
The decision was a loss for Amgen, which had claimed that Sanofi and Regeneron's drug Praluent infringed on its patents for the drug Repatha.
Is the new class of cholesterol drugs the next battleground for payers and prescribers?
With high price tags and a tougher path to generic as a biologic, payer pressure on clinicians to raise adherence for PCSK9 drugs to new heights will be keen.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.